Publications by authors named "N A M Guman"

Background: Guidelines suggest indefinite anticoagulation after unprovoked venous thromboembolism (VTE) unless the bleeding risk is high, yet there is no consistent guidance on assessing bleeding risk.

Objectives: This study aimed to evaluate the performance of 5 bleeding risk tools (RIETE, VTE-BLEED, CHAP, VTE-PREDICT, and ABC-Bleeding).

Methods: PLATO-VTE, a prospective cohort study, included patients aged ≥40 years with a first unprovoked VTE.

View Article and Find Full Text PDF

 Current guidelines recommend either low-molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) as first-line treatment in cancer-associated venous thromboembolism (VTE).  This study aimed to investigate treatment regimens for cancer-associated VTE over the past 5 years, explore predictors for initial treatment (LMWH vs. DOAC), and to assess the risks of recurrent VTE and bleeding.

View Article and Find Full Text PDF

Background: It is unclear how often cancer patients with acute pulmonary embolism (PE) are discharged from the emergency department (ED) or outpatient clinic and whether direct discharge is safe. We assessed treatment setting and early safety outcomes in cancer patients with acute symptomatic and incidental PE.

Methods: Cancer patients diagnosed with PE at the ED or outpatient clinic between August 2017 and May 2021 were included in Four Cities VTE Cancer, a Dutch multicenter retrospective cohort study.

View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma patients have a high risk of developing venous thromboembolism (VTE), and researchers aim to understand the genetic and signaling factors that contribute to this risk.
  • Using RNA sequencing, researchers compared gene expression profiles of glioblastoma patients with VTE to those without and identified 1246 differentially expressed genes, including GLI1, which is linked to the Sonic Hedgehog signaling pathway.
  • The findings suggest that the Sonic Hedgehog pathway may play a significant role in the risk of VTE among glioblastoma patients, particularly those with certain tumor subtypes.
View Article and Find Full Text PDF